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Background: The acquired form of idiopathic thrombotic thrombocytopenic purpura 
(TTP) is an autoimmune disease, in which the underlying deficiency of the ADAMTS13 
protease is caused by autoantibodies, predominantly of the IgG isotype. Certain HLA-
DR-DQ haplotypes were associated with the risk of developing TTP.
Objectives: To investigate the development of the ADAMTS13-specific antibody 
response during the course of the disease, we analyzed the concentration, subclass 
distribution, and inhibitory potential of anti-ADAMTS13 IgG autoantibodies in samples 
of TTP patients drawn during the first acute phase, in remission, and during relapse. 
Additionally, we compared the anti-ADAMTS13 IgG levels between patients carrying 
and not carrying risk and protective HLA-DR-DQ haplotypes.
Patients and Methods: We determined the anti-ADAMTS13 IgG concentration and 
subclass distribution in 101 antibody-positive samples of 81 acquired TTP patients 
by ELISA methods. The presence and semi-quantitative amount of anti-ADAMTS13 
inhibitors were determined in 97 of 100 deficient samples, and the specific inhibitory 
potential of anti-ADAMTS13 autoantibodies was determined in 49 selected samples, by 
mixing ADAMTS13-activity assays. HLA-DR-DQ typing and haplotype prediction were 
performed in 70 of the above patients.
results: We found that IgG1 and IgG4 were the predominant subclasses, present in 
almost all samples. While IgG1 was the dominant subclass in almost half of the samples 
taken during the first acute episode, IgG4 was dominant in all samples taken during or 
following a relapse. The inhibitory potential of the samples correlated with levels of the 
IgG4 subclass. Anti-ADAMTS13 antibodies of IgG4-dominant samples had higher spe-
cific inhibitory potentials than IgG1-dominant samples, independently of disease stage. 
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Interestingly, we found that patients carrying the protective DR7-DQ2 and DR13-DQ6 
haplotypes had higher anti-ADAMTS13 IgG levels.
conclusion: Our results indicate that IgG4 becomes the dominant subtype at some 
point of the disease course, apparently before the first relapse, parallel to the increase 
in inhibitory potential of the anti-ADAMTS13 autoantibodies. Furthermore, we found an 
association between the genetic background and the antibody response in TTP.
Keywords: thrombotic thrombocytopenic purpura, anti-aDaMTs13 autoantibodies, igg subclasses, aDaMTs13-
inhibitors, hla-DrB1-DQB1 haplotypes
inTrODUcTiOn
Idiopathic thrombotic thrombocytopenic purpura (TTP) is a 
rare but life-threatening disease, which belongs to the group of 
thrombotic microangiopathies, and presents with episodes of 
severe thrombocytopenia, microangiopathic hemolytic anemia 
(MAHA) with fragmentation of erythrocytes, and end-organ 
dysfunction caused by microvascular thrombosis (1). The patho-
genic thrombi consist primarily of platelets bound to the ultra-
large form of Von Willebrand factor (ULVWF) (2, 3). ULVWF 
multimers are supposed to be cleaved by the ADAMTS13 protease 
(4, 5). In the idiopathic form of TTP, however, the activity of the 
ADAMTS13 enzyme is deficient, resulting in increased levels of 
ULVWF, which are able to bind and activate platelets (2, 6).
The underlying ADAMTS13 deficiency is caused by ADAMTS13 
mutations in the rare, congenital form of TTP (7), whereas the 
more common, acquired form of TTP is an autoimmune disease, 
in which autoantibodies against the ADAMTS13 enzyme are 
responsible for its deficiency (8, 9).
Some of these antibodies are inhibitory, directly blocking 
the enzymatic activity of the protease (8, 9), while some are 
non-inhibitory (10). Irrespective of the inhibitory potential of 
the autoantibodies, they can also contribute to the ADAMTS13 
deficiency by promoting the clearance of the enzyme from the 
circulation (11–13).
Anti-ADAMTS13 autoantibodies are predominantly of the 
IgG isotype, although IgM and IgA class antibodies have also 
been described in some cases (10, 14–18). IgG antibodies can 
be subdivided into four subclasses based on differences in their 
Fc regions. These differences affect their ability to bind com-
plement or Fc receptors of effector cells, resulting in distinct 
immunological properties. Most anti-ADAMTS13 antibodies 
belong to the IgG1 and IgG4 subclasses (16–19); IgG1 and IgG3 
levels were found to be associated with the clinical severity of 
the episode (16, 17) and IgG4 levels with the risk of relapse (16).
Relapses (acute episodes following complete remission) occur 
in about one-third of TTP patients (20). Anti-ADAMTS13 
auto antibody levels are usually higher during the acute episodes, 
and lower or undetectable during remission. However, free 
antibodies or immune complexes may also be present during 
remission, leading to deficient ADAMTS13-activity in a subset 
of remission patients (18, 21), which increases the risk of disease 
relapse (15, 21).
During the disease course often spanning over decades, the 
immune response against ADAMTS13 may go through certain 
changes in response to the prolonged antigen stimulation or 
to the various therapies. The primary goal of this study was to 
investigate the changes in the immune response by comparing 
immunological properties (concentration, subclass distribution, 
and inhibitory potential) of the anti-ADAMTS13 IgG autoanti-
bodies in different disease stages.
The antibody response against a protein antigen and isotype 
switching of autoantibodies to the IgG class implies the role of 
helper T  cells and antigen presentation in the development of 
acquired TTP. During antigen presentation, peptides of extracel-
lular protein antigens are presented to CD4-positive helper T cells 
via the HLA-DR and DQ antigens, which are inherited in linkage 
in the form of DR-DQ haplotypes. Indeed, it has been shown 
that certain HLA-DR and DQ alleles, or DR-DQ haplotypes 
are associated with increased or decreased risk of TTP (22–25). 
However, whether these HLA-DR and DQ alleles also influence 
the character of the immune response to ADAMTS13 has not 
yet been studied. Therefore, another aim of this study was to 
investigate whether the concentration and subclass distribution 
of anti-ADAMTS13 IgG antibodies differ in individuals carrying 
risk or protective HLA-DR-DQ haplotypes.
PaTienTs anD MeThODs
Patient and sample selection
We analyzed 101 anti-ADAMTS13 IgG-positive samples of 81 
acquired TTP patients investigated in our laboratory between 
August 2007 and March 2017. Our laboratory is providing diag-
nostic services for patients from Hungary and nearby countries 
suspected of having thrombotic microangiopathies. The diag-
nosis of acquired TTP was based on the following criteria: (1) 
thrombocytopenia (platelet count below 150  G/L) and MAHA 
(Coombs-negative anemia, elevated LDH, schistocytes on the 
blood smear); (2) deficient ADAMTS13 activity [<10%, meas-
ured by the FRETS-VWF73 assay (fluorescence resonance energy 
transfer-based method using a 73-amino-acid synthetic peptide), 
as described below]; and (3) detectable anti-ADAMTS13 auto-
antibodies (by mixing activity assays or ELISA, as described 
below). One hundred and thirteen patients fulfilled the above 
criteria at a time point during the inclusion period.
Blood samples sent to our laboratory were taken either dur-
ing an acute episode [before the initiation or during plasma 
exchange (PEX) therapy] or in remission. Complete remission 
was defined as normal platelet count (>150 G/L) and no signs 
FigUre 1 | Scheme of patient and sample selection. Abbreviations: MAHA, microangiopathic hemolytic anemia; aTTP, acquired idiopathic thrombotic 
thrombocytopenic purpura.
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of hemolysis, without new or worsening clinical symptoms for 
at least 30 days after stopping PEX therapy. (In the following, we 
refer to complete remission as ‘remission’.) Relapse was defined 
as a new TTP episode following remission.
The blood samples were obtained by venipuncture or from a 
central venous catheter; serum/plasma and cells were separated 
by centrifugation either in our laboratory, if transport time was 
less than 4  h, or on the site of blood collection. Samples were 
shipped to our laboratory in cooled packages (4°C) in case of 
whole blood samples, or frozen (−20°C) in case of separated 
samples, and were stored at −70°C until measurements. Sodium 
citrate-anticoagulated plasma or native serum samples were used 
for the determinations of ADAMTS13 activity and autoantibody 
concentrations.
All ADAMTS13-deficient (<10% activity) samples of acquired 
TTP patients available in our laboratory were tested for the 
presence of anti-ADAMTS13 IgG. A randomly selected subset 
of TTP patients’ samples with decreased but not deficient 
ADAMTS13 activities (between 20 and 40%) were also tested, 
but none of the 15 samples were anti-ADAMTS13 IgG posi-
tive. One hundred and nine available samples were found to be 
anti-ADAMTS13 IgG positive according to the Technozym 
ADAMTS13-Inh® assay described below. These samples were 
selected for the subclass distribution analysis of anti-ADAMTS13 
IgG autoantibodies. The determination was successful in 101 
samples of 81 patients, 8 of the above samples contained too 
low antibody concentrations for the analysis. The steps of the 
patient and sample selection are summarized in Figure 1.
All available acute samples (from the first acute episode or 
from a relapse) with relative proportions of IgG4 over 70% or 
below 30%, and all available remission samples were selected for 
the determination of the specific inhibitory potentials of anti-
ADAMTS13 autoantibodies. Thirty-five of the 50 selected acute 
samples and 14 of the 21 remission samples were available for the 
analysis in sufficient quantities.
Seventy of the included patients had available samples for 
DNA isolation, and HLA-DR and DQ typing.
The present study was conducted in accordance with the 
Declaration of Helsinki, written informed consent was obtained 
from all participating patients, and the study was approved by 
the Human Research Ethics Committee.
Determination of aDaMTs13 activity and 
anti-aDaMTs13 inhibitors
ADAMTS13 activity was measured by a FRETS-VWF73 assay 
described earlier (26) (AnaSpec Inc., Fremont, CA, USA).
The presence and semi-quantitative amount of functional 
anti-ADAMTS13 inhibitors were determined by measuring the 
ADAMTS13 activity of a 1:1 mixture of 50 µL deficient patient 
sample and 50  µL normal, pooled human citrated plasma or 
serum sample (with a nominal ADAMTS13 activity of 100%) 
following 2 h of incubation at 37°C. The activity of the mixed 
sample was compared to that of 100 µL incubated normal human 
sample (100%). An ADAMTS13 activity below 50% was consid-
ered positive for the presence of inhibitors, with lower activities 
implying stronger inhibition.
Determination of the Total anti-aDaMTs13 
igg concentration
Total anti-ADAMTS13 IgG concentrations were measured 
by a commercial ELISA kit (Technozym ADAMTS-13 Inh®, 
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Technoclone GmbH, Vienna, Austria). According to the manu-
facturer’s recommendation, samples with anti-ADAMTS13 IgG 
concentrations above 15 U/mL were considered positive.
Determination of the subclass Distribution 
of anti-aDaMTs13 igg antibodies
We developed a novel ELISA-based method to precisely 
determine the subclass distribution of anti-ADAMTS13 IgG 
antibodies, which is described in detail in the Data Sheet S1 in 
Supplementary Material.
Briefly, we prepared calibrator plates by coating two 
columns of 96-well polystyrene microtiter plates (Greiner 
Bio One International GmbH, Kremsmünster, Austria) with 
known concentrations of purified human antibodies of each 
IgG subclass (Abcam, Cambridge, UK; Ref. No: IgG1—
ab90283, IgG2—ab90284, IgG3—ab118426, IgG4—ab90286). 
We prepared two fold dilution series from each IgG subclass 
in bicarbonate buffer (pH 9.8), with concentrations ranging 
from 1,000 to 15.6 ng/mL and 0 ng/mL; 100 µL/well of these 
calibrators were loaded on the plate in duplicates and were 
incubated overnight at 4°C. The calibrator plates were washed, 
blocked by adding 110  µL/well of phosphate buffered saline 
(pH 7.4) containing 0.5% gelatine, and following an incubation 
of 50 min at room temperature, washed again three times by 
adding 200 µL/well of the washing buffer from the Technozym 
ADAMTS-13 Inh® kit.
The samples were diluted in the diluent of the Technozym 
ADAMTS-13 Inh® kit. The dilution factors were adjusted to 
the total anti-ADAMTS13 IgG concentrations of the samples, 
as described in the Data Sheet S1 in Supplementary Material; 
dilutions between 1:12.5 and 1:600 were used. 100  μL/well of 
each diluted sample was added to four wells of the test plate from 
the Technozym ADAMTS-13 Inh® kit, coated with recombi-
nant ADAMTS13 protein, and were incubated for 1 h at room 
temperature, simultaneously with the blocking of the calibrator 
plate. The plates were then washed five times.
Then, 100 μL/well of subclass-specific antibodies was added 
to the respective columns of the calibration plate and to one of 
the four wells containing a given sample on the test plate. We 
used HRP-conjugated mouse anti-human antibodies against the 
Fc region (Southern Biotech, Birmingham, AL, USA; Ref. No.: 
anti-IgG1—9054-05, anti-IgG2—9060-05, anti-IgG3—9210-05, 
anti-IgG4—9200-05) in the following dilutions: IgG1 and 
IgG2—1:1,000, IgG3—1:10,000, IgG4—1:5,000. Both (test and 
calibrator) plates were incubated for 1  h at room temperature, 
and washed six times. The plates were then developed by add-
ing 100  μL/well of TMB (Novex® TMB by life technologies, 
Frederick, MD, USA; Ref. No.: 00-2023). The substrate reaction 
was stopped by adding 50 μL/well of H2SO4 (4N) when the color 
reaction seemed to be optimal. Importantly, wells incubated by 
the same subclass-specific secondary antibodies were developed 
for the same time.
Absorbance of samples and calibrators was measured at 450 nm, 
with a reference wavelength of 620 nm. Calibrator curves were 
generated based on the optical density values of calibrator wells 
with known amount of bound antibodies for each subclass. The 
amounts of bound anti-ADAMTS13 antibodies of each IgG 
subclass were interpolated directly from the respective calibra-
tor curve in the case of patient samples. Then, we determined 
the total amount of bound anti-ADAMTS13 antibodies by 
summing the amounts of all four subclasses. The proportion of 
each antibody subclass was calculated by dividing the bound 
amount of the respective subclass by the total amount of bound 
anti-ADAMTS13 antibodies.
calculation of the absolute 
concentrations of anti-aDaMTs13 
antibodies of Distinct subclasses
Absolute concentrations of anti-ADAMTS13 antibodies of 
each subclass were calculated by multiplying the total anti-
ADAMTS13 IgG concentration (determined by the Technozym 
ADAMTS-13 Inh® kit) by the proportion of the given subclass, 
determined as described above.
Determination of the specific inhibitory 
Potential of anti-aDaMTs13 antibodies
Selected patient samples were diluted in phosphate buffered saline 
(pH 7.4) to a degree calculated by the total anti-ADAMTS13 IgG 
concentrations, in order to obtain equal final anti-ADAMTS13 
IgG concentrations of 25 U/mL. The diluted samples were incu-
bated with normal, pooled human citrated plasma or serum 
samples (according to the patient sample type; with nominal 
ADAMTS13 activity of 100%) in ratios of 3:1, 1:1, and 1:2 in a 
final volume of 60 µL, and were incubated for 2 h at 37°C. The 
ADAMTS13 activities of the mixed samples were measured as 
described above and compared to those of incubated pooled 
normal human samples (100%). A low ADAMTS13 activity of 
the mixed sample indicated a high specific inhibitory potential 
of the given anti-ADAMTS13 IgG antibodies and vice versa.
hla Typing and haplotype Prediction
Low-resolution HLA-DRB1 and DQB1 typing was performed 
by polymerase chain reaction with sequence-specific oligo-
nucleotide probe hybridization (PCR-SSO) (One Lambda, 
Canoga Park, CA, USA) at the Laboratory of Transplantation 
Immunogenetics in Budapest, and the HLA-DRB1-DQB1 
haplotypes were predicted by the PHASE (v2.1) program 
(27, 28), as described previously (25).
statistical analysis
As the distribution of variables was not normal in most cases, 
medians and interquartile (IQ) ranges are represented, and 
nonparametric statistical tests were used. Correlations between 
antibody concentrations and the ADAMTS13 activity of mixed 
samples were calculated by the Spearman rank correlation test. 
Antibody concentrations or proportions in distinct groups of 
patients were compared by the Mann–Whitney test. (When 
comparing parameters between two disease stages, the patients 
with paired samples in both disease stages were excluded in 
order that the two groups become independent.) The numbers of 
IgG1- or IgG4-dominant patients in two groups were compared 
by Fisher’s exact test. Two-way ANOVA was used to compare 
the ADAMTS13 activities of diluted patient samples mixed 
FigUre 2 | Number of patients and samples tested for anti-ADAMTS13 IgG 
subclass distribution according to disease stage. The number of common 
patients between disease stage groups are shown in the small boxes over 
the connecting lines.
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with pooled normal human samples. Findings with p-values 
below 0.05 were considered statistically significant. Statistical 
calculations were performed by the GraphPad Prism 5 software 
(GraphPad Softwares Inc., La Jolla, CA, USA).
resUlTs
Description of the Patient cohort
From the 113 patients in our registry who fulfilled the criteria 
of acquired idiopathic TTP during the inclusion period, 81 
patients had anti-ADAMTS13 IgG-positive samples appropriate 
for the determination of IgG subclasses. Their median age was 
38 (IQ range: 29–50) years; 62 (76.5%) of them were females 
and 19 (23.5%) were males. The median follow-up time was 21.9 
(0.6–75.7) months, during which 26 patients (32.0%) had at least 
one relapse. Nine of 61 patients (14.8%) died during the first 
acute episode, and 1 of 19 patients (5.3%) died during the relapse 
in which the tested samples were drawn. Sixty-three acute sam-
ples were taken before the first PEX therapy, and 17 acute samples 
were taken following the first PEX session. Three relapse samples 
and eight remission samples were taken after rituximab therapy 
(one and six samples, respectively, were taken within 1 year of 
receiving rituximab). Other immunosuppressive drugs (cyclo-
phosphamide, azathioprine, vincristine) were applied before the 
collection of four samples (two, two, and one, respectively).
anti-aDaMTs13 igg levels and subclass 
Distribution in all analyzed acquired  
TTP samples
We determined the concentration and subclass distribution 
of anti-ADAMTS13 IgG autoantibodies in 101 samples of the 
above described patients. The distribution of samples based on 
disease stage is summarized in Figure 2.
All tested samples were anti-ADAMTS13 IgG positive (above 
15 U/mL). Median anti-ADAMTS13 IgG level was 66 U/mL, with 
an IQ range of 35.6–158.0 U/mL.
Anti-ADAMTS13 IgG antibodies were mostly of the IgG1 
and IgG4 subclasses. IgG1 was the dominant subclass (i.e., the 
subclass with the highest proportion) in 28 of the 101 samples 
(27.7%), whereas IgG4 was dominant in 71 (70.3%) of them. IgG3 
was the dominant subclass only in two samples (2.0%), whereas 
IgG2 was not dominant in any of the samples. The median pro-
portion of IgG4 was the highest, 66.0% (31.5–76.0%) and that of 
IgG1 was 32.0% (24.0–51.5%), followed by IgG3 and IgG2 with 
0.0% (0.0–5.5% and 0.0–2.5%, respectively). IgG1 was present in 
97 samples (96.0%), whereas IgG4 was detectable in 94 of them 
(93.1%). IgG3 was detectable in 51 samples (50.5%), mostly in 
IgG1-dominant ones: it was present in 25 (89.3%) of the 28 IgG1-
dominant samples. IgG2 could be detected in 41 samples (40.6%).
The proportion of neither of the IgG subclasses correlated 
with the total anti-ADAMTS13 IgG concentration. The concen-
trations of IgG subclasses correlated positively with each other, 
except for the concentrations of IgG3 and IgG4, which showed a 
strong negative correlation (r = −0.480, p < 0.0001).
There was no statistical difference between the total anti-
ADAMTS13 IgG concentration and subclass distribution of acute 
samples taken before or after the first PEX therapy. The number 
of patients receiving rituximab or other immunosuppressive 
drugs was too low to perform statistical analyses, but their anti-
ADAMTS13 IgG results were not substantially different from 
those of untreated patients.
anti-aDaMTs13 igg levels and subclass 
Profile in Different stages of the Disease
Anti-ADAMTS13 IgG subclass concentrations in distinct disease 
stages are shown in Figure 3.
The anti-ADAMTS13 IgG concentrations and subclass dis-
tribution in independent samples drawn during the first acute 
phase and relapse are shown in Table 1. Patients with samples 
from both disease stages were excluded from the analysis. The 
age and gender distribution did not differ between the two 
groups. The total IgG levels tended to be higher in samples 
drawn in the first episode than in relapse [77.5 (47.6–161.8) vs. 
42.3 (28.0–81.9) U/mL], but the difference was not statistically 
significant. During the first acute episode, IgG4 was the domi-
nant subclass in 30 (52.6%) of the 57 samples, whereas IgG1 was 
dominant in 27 (47.4%) of them. In relapse samples, however, 
IgG4 was the dominant subclass in all 15 samples.
Similarly, IgG4-dominance could be observed in all 11 remis-
sion samples drawn after a relapse. In contrast, one sample drawn 
FigUre 3 | Concentration and subclass distribution of anti-ADAMTS13 IgG autoantibodies in the first acute phase, in relapse, and in remission. The horizontal line 
marks the cutoff value (15 U/mL).
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in remission following the first acute episode was IgG1-dominant 
and two samples were IgG3-dominant. The anti-ADAMTS13 IgG 
profiles in independent samples from remission following the 
first acute episode and following a relapse are shown in Table 2.
Four patients had events of unexplained thrombocytopenia in 
their anamnesis prior to the diagnosis of TTP. Interestingly, all 
four of these patients’ samples, drawn during the episode when 
TTP was diagnosed, were IgG4 dominant.
Fifteen patients had multiple samples, and the dominant 
subclasses in these samples are shown in Figure  4. The anti-
ADAMTS13 IgG profiles of four patients with a sample from the 
first episode were initially IgG1-dominant, while all other patients 
were initially IgG4 dominant. In remission following the first acute 
episode, two of the four initially IgG1-dominant patients switched 
to an IgG4-dominant profile. However, in spite of the higher num-
bers of initially IgG4-dominant patients, a dominance switch in 
the other direction (from IgG4 to IgG1) was not observed. One 
initially IgG4-dominant patient had a non-deficient remission 
sample, though, which proved to be IgG3-dominant. All deficient 
samples taken during or following a relapse were IgG4 dominant.
Taken together, whereas a number of samples drawn during or 
following the first acute episode were IgG1- or IgG3-dominant, 
TaBle 1 | Comparison of levels and subclass distribution of anti-ADAMTS13 
IgG antibodies between the first acute episode and relapse.
First episode relapse
clinical data
Number of individuals 57 15
Age (years) 41 (29–54) 35 (28–44)
Gender (female/male) 42/15 12/3
Current episode No 1 3 (2–5)
Months since 
diagnosis of thrombotic 
thrombocytopenic purpura
0 69 (46–230)
Total anti-aDaMTs13 igg concentration (U/ml)
IgG 77.5 (47.6–161.8) 42.3 (28.0–81.9) p = 0.0831
Proportion of igg subclasses (%)
IgG1 42.0 (30.6–68.8) 24.3 (21.0–28.8) p = 0.0002
IgG2 0.0 (0.0–2.6) 1.1 (0.0–2.8) p = 0.2230
IgG3 2.2 (0.0–9.7) 0.0 (0.0–0.2) p = 0.0086
IgG4 49.7 (14.0–68.3) 73.6 (65.0–78.4) p = 0.0004
concentration of igg subclasses (U/ml)
IgG1 35.7 (17.5–96.6) 12.8 (6.0–19.9) p = 0.0066
IgG2 0.0 (0.0–2.8) 1.2 (0.0–3.8) p = 0.1826
IgG3 1.6 (0.0–8.2) 0.0 (0.0–0.1) p = 0.0061
IgG4 25.2 (8.6–62.6) 28.5 (21.7–59.7) p = 0.1552
Dominant subclasses (number of patients, %)
IgG1 27 (47.4%) 0 (0%) p = 0.0005
IgG4 30 (52.6%) 15 (100%)
Results of independent samples are shown; patients having samples in both disease 
stages were excluded from the analysis in order to allow statistic comparison of the 
independent groups. (Similar results are obtained if all results are involved.) Values are 
expressed as median (interquartile range). The subclass with the highest proportion 
was considered dominant. Significantly different values are shown in bold.
TaBle 2 | Levels and subclass distribution of anti-ADAMTS13 IgG antibodies  
in clinical remission following the first acute episode and following a relapse.
remission after 
first episode
remission  
after relapse
clinical data
Number of individuals 9 8
Age (years) 34 (20–45) 34 (30–45)
Gender (female/male) 8/1 8/0
No of previous episode 1 3 (2–4)
Months since first episode 7 (3–35) 72 (42–143)
Total anti-aDaMTs13 igg concentration (U/ml)
IgG 45.0 (31.5–73.3) 60.2 (30.6–592.2)
Proportion of igg subclasses (%)
IgG1 23.8 (19.2–41.7) 25.3 (22.1–31.5)
IgG2 0.0 (0.0–4.9) 0.0 (0.0–2.9)
IgG3 0.0 (0.0–2.0) 0.0 (0.0–0.6)
IgG4 71.4 (32.6–80.8) 73.0 (67.2–76.9)
concentration of igg subclasses (U/ml)
IgG1 17.6 (6.7–39.4) 14.0 (8.1–152.0)
IgG2 0.0 (0.0–3.3) 0.0 (0.0–18.3)
IgG3 0.0 (0.0–1.0) 0.0 (0.0–0.3)
IgG4 29.6 (10.0–49.85) 45.7 (24.2–388.5)
Dominant subclasses (number of patients)
IgG1 or IgG3 2 (22%) 0 (0%)
IgG4 7 (78%) 8 (100%)
Results of independent samples are shown; only one (the first) remission sample of 
each patient was involved in the analysis. Values are expressed as median (IQ range). 
The subclass with the highest proportion was considered dominant. No statistical 
analysis was performed because of the low number of samples.
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all deficient samples taken during or following a relapse were 
IgG4 dominant.
aDaMTs13 inhibition and its association 
with anti-aDaMTs13 igg levels
ADAMTS13 activity was deficient in all samples except a remis-
sion sample with a low level (15.8  U/mL) of anti-ADAMTS13 
IgG antibodies. The presence of anti-ADAMTS13 inhibitors was 
determined in 97 of the 100 deficient samples by a mixing FRET-
vWF73 assay. The ADAMTS13 activity of patient samples mixed 
and incubated together with equal amounts of normal human 
plasma or serum [2.0% (0.0–11.5%)] implies the strength of the 
anti-ADAMTS13 inhibition in the sample, with lower activities 
indicating stronger inhibition and vice versa.
The ADAMTS13 activities of patient samples mixed and 
incubated together with equal amounts of pooled normal 
human samples showed a negative correlation with the total 
anti-ADAMTS13 IgG levels (r = −0.326, p = 0.011). However, an 
even stronger negative correlation was found with the levels of 
antibodies of the IgG4 subtype (r = −0.473, p < 0.0001) (shown 
in Figure 5), whereas no other subclass showed a correlation with 
the activities of mixed samples (IgG1: r = −0.134, p = 0.191; IgG2: 
r = −0.0127, p = 0.901; IgG3: r = 0.169, p = 0.098). The negative 
correlation between the activity of mixed samples and anti-
ADAMTS13 IgG (r = −0.278, p = 0.034) or IgG4 (r = −0.302, 
p =  0.021) was also significant if only samples from the first 
acute phase were analyzed. Thus, the strength of ADAMTS13 
inhibition, inferred from the activity of the mixed patient sample, 
correlated positively with anti-ADAMTS13 IgG4 levels.
specific inhibitory Potential of anti-
aDaMTs13 antibodies according to igg 
subclass Distribution and Disease stage
To directly assess the specific inhibitory potentials of patient samples, 
we diluted a selected set of samples to obtain equal (25 U/mL) 
anti-ADAMTS13 IgG concentrations. Thirty-five acute samples 
with low (<30%) or high (>70%) relative proportions of IgG4, 
and 14 remission samples were analyzed. The diluted samples 
were mixed and incubated with pooled normal human samples 
in three different ratios (3:1, 1:1, 1:2). The ADAMTS13 activi-
ties of the mixtures were compared according to disease stage 
and dominant IgG subclass, with lower activities indicating 
higher inhibitory potentials and vice versa. As it can be seen on 
Figure 6, IgG4-dominant samples clearly have a stronger inhibi-
tory potential than IgG1-dominant samples, and this difference 
is independent of the stage of the disease; i.e., IgG4-dominant 
samples taken in the first acute episode, in a relapse and in remis-
sion have similar inhibitory capacities.
associations of anti-aDaMTs13 igg 
levels and subclass Distribution With 
risk and Protective hla-Dr-DQ 
haplotypes
The HLA-DR-DQ haplotypes were determined in 70 of the 81 
patients. Forty-seven of the above patients carried risk (DR11- 
DQ3 or DR15-DQ6) and nine of them protective (DR7-DQ2 or 
FigUre 4 | Dominant subclasses in samples of patients with multiple samples. Dashed arrows show a change in the dominant subclass, arrows indicating  
a change from IgG1 to IgG4 appear in bold. The only sample with normal ADAMTS13 activity (with low positive levels of anti-ADAMTS13 antibodies) is marked  
by an asterisk.
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FigUre 5 | Associations of anti-ADAMTS13 IgG1 and IgG4 levels with the ADAMTS13 activity measured in 97 of the 100 deficient patient samples following  
mixing and incubation with equal amounts (1:1 ratio) of pooled normal human plasma or serum.
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AC
B
FigUre 6 | Specific inhibitory potentials of samples from different disease stages and with different IgG4 proportions. Patient samples were diluted in order to have 
equal (25 U/mL) anti-ADAMTS13 concentrations, diluted samples were mixed and incubated in different ratios with normal pooled human citrated plasma or serum, 
and ADAMTS13 activities of the mixed samples were measured. Low activities of mixed samples indicate a strong inhibitory potential and vice versa. (a) Specific 
inhibitory potentials of acute samples. Mean and SEM are shown for all mixing ratios. All deficient samples from the relapse phase were IgG4 dominant; none had 
IgG4 proportions below 30%. (B) Specific inhibitory potentials of all samples stratified by dominant IgG subclass. (c) Specific inhibitory potentials of IgG4 dominant 
samples stratified by disease stage. All deficient samples taken during or following a relapse were IgG4 dominant.
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DR13-DQ6) haplotypes, two of these patients carried both. The 
proportion of anti-ADAMTS13 IgG subclasses did not differ 
between patients carrying and not carrying either risk or protec-
tive haplotypes.
However, when comparing the first available acute sample 
of each patient with known HLA-DR-DQ haplotypes, we found 
that the concentration of anti-ADAMTS13 autoantibodies were 
higher in patients carrying, than in those not carrying protec tive 
haplotypes [280.4 (142.8–687.0) vs. 65.7 (42.1–111.4) U/mL, 
p =  0.0003] (Figure  7A). Conversely, no difference could be 
observed between patients carrying and not carrying risk hap-
lotypes. There was no clear association between anti-ADAMTS13 
IgG levels and the number of risk or protective haplotypes car-
ried (gene dosage) (Figure 7B).
Comparing samples from the first acute episode, we found that 
the anti-ADAMTS13 IgG levels were higher in patients carry-
ing protective haplotypes than in those not carrying protec tive 
haplotypes [240.2 (122.9–533.1) vs. 67.1 (43.6–152.0)  U/mL, 
p = 0.0025] (Figure 7C). Interestingly, patients not carrying pro-
tective haplotypes had lower total anti-ADAMTS13 IgG levels 
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during relapse than during the first acute episode [42.3 (31.0–67.4) 
vs. 67.1 (43.6–152.0) U/mL, p = 0.0291]. No such trend could be 
observed in patients carrying protective haplotypes.
DiscUssiOn
In order to investigate the changes in the antibody response 
against ADAMTS13 during the course of TTP, we analyzed the 
amount, subclass distribution, and inhibitory potential of anti-
ADAMTS13 autoantibodies in 101 samples of 81 TTP patients, 
drawn in different stages of the disease.
We found that most anti-ADAMTS13 IgG autoantibodies 
belonged to the IgG1 and IgG4 subclasses, which were present 
in most samples. Whereas almost half of the samples drawn 
during the first acute episode were IgG1-dominant, all samples 
taken during or following a relapse were IgG4 dominant. The 
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FigUre 7 | Anti-ADAMTS13 IgG levels in patients carrying or not carrying protective (DR7-DQ2 or DR13-DQ6) or risk (DR11-DQ3 or DR15-DQ6) HLA-DR-DQ 
haplotypes. Medians and interquartile ranges are shown. (a,B) Anti-ADAMTS13 IgG levels in the first available acute sample (either from the first acute episode  
or from relapse) of each patient with available HLA-DR-DQ data. The numbers below panel (B) show the number of risk or protective haplotypes carried by the 
patient. (c) Samples from the first acute episode and from relapse. +: protective haplotype carrier, −: not carrying protective haplotypes.
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inhibitory potential of samples increased parallel to the change 
to IgG4-dominance, and correlated with the levels of anti-
ADAMTS13 IgG4. Patients carrying protective DR7-DQ2 and 
DR13-DQ6 haplotypes had higher total anti-ADAMTS13 IgG 
levels compared to those not carrying protective haplotypes. 
Patients who did not carry protective haplotypes had lower total 
anti-ADAMTS13 IgG levels during relapse than during the first 
acute episode.
During the inclusion period, 113 patients were diagnosed 
with acquired idiopathic TTP in our laboratory, 81 of the above 
patients had altogether 101 appropriate samples for the determi-
nation of anti-ADAMTS13 IgG levels and subclass distribution. 
The presence and amount of anti-ADAMTS13 inhibitors were 
tested in 97 of the above samples, and the specific inhibitory 
potential of anti-ADAMTS13 antibodies were determined in 49 
of them. HLA-DR-DQ haplotypes were determined in 70 TTP 
patients. The age and gender distribution and the mortality and 
relapse rate of patients in our cohort are consistent with data 
from the literature (20, 29).
In agreement with previous studies (16–19), we found that 
the anti-ADAMTS13 IgG autoantibodies belonged primarily 
to the IgG1 and IgG4 subclasses, which were present in most 
samples, whereas IgG2 and IgG3 were present only in smaller 
subsets of samples, and only in lower concentrations. In contrast 
with previous observations (16), we found that the proportions, 
but not the absolute amounts of IgG1 and IgG4 showed an 
inverse correlation. On the contrary, concentrations of IgG1 and 
IgG4 were positively correlated in our study, possibly because 
antibody levels were more variable than the proportions of the 
subclasses, so samples with high or low total anti-ADAMTS13 
concentrations contained high or low concentrations of both 
subclasses, respectively. On the other hand, the levels of IgG3, 
found mainly in IgG1-dominant samples, showed a strong 
inverse correlation with IgG4 levels, supporting a difference in 
the polarity of the immune response.
The IgG1 and IgG3 subclasses are potent inducers of inflam-
mation as they can effectively bind to Fcγ receptors and can 
activate the classical pathway of the complement system. IgG4, 
on the contrary, tends to be anti-inflammatory, as it cannot 
activate the complement system via the classical pathway, and 
binds Fcγ molecules with low affinity (30, 31). Moreover, IgG4 
molecules are capable of exchanging one heavy chain and the 
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associated light chain with other IgG4 molecules, resulting in 
bispecific, functionally monovalent antibodies (32). Because 
of their functional monovalency, they are unable to form large 
immune complexes, which further attenuate their inflam-
matory property (31, 33). In spite of their low inflammatory 
potential, IgG4 antibodies are involved in the pathogenesis of 
numerous autoimmune disorders (34, 35). IgG4 antibodies are 
often produced following prolonged antigenic stimulation (36). 
Accordingly, IgG4 seems to emerge as the dominant subclass 
in the ADAMTS13-specific antibody response in later stages of 
acquired TTP.
Our study provides independent validation of the polarized 
nature of autoantibody development to ADAMTS13 in TTP. 
In agreement with the results of Ferrari et  al. (16), whereas 
IgG1 was the predominant subclass in almost half of the 
samples drawn during the first acute episode, all deficient 
samples drawn during or following a relapse were IgG4 domi-
nant (Table 1; Figure 3). Moreover, all four patients who had 
unexplained events of thrombocytopenia before the diagnosis 
of TTP, corresponding to subclinical episodes of the disease, 
had IgG4-dominant anti-ADAMTS13 antibody response at 
the time of the first clinical acute episode. Besides the above 
comparison of independent samples, results of patients with 
multiple samples further support this observation: IgG4 was the 
dominant subclass in all samples taken in relapse, or in remis-
sion following a relapse. Two of the four patients with initially 
IgG1-dominant samples had IgG4-dominant samples already 
in remission following the first episode (neither of them has 
relapsed to date). Contrarily, none of the patients with initially 
IgG4-dominant samples had subsequent IgG1-dominant sam-
ples. One of them had an IgG3-dominant sample, however, with 
normal ADAMTS13 activity, which suggests the disappearance 
or ceased antibody production of the IgG4-producing clones 
(Figure 4).
The observation on the restricted clonality, i.e., the lack of 
IgG1-dominant immune response to ADAMTS13 in relapse of 
TTP, is intriguing. The antibody response against ADAMTS13 in 
TTP is a polyclonal one, as was shown by cloning ADAMTS13-
specific B cells (37–40). A single B cell clone produces antibodies 
of exclusively one subclass, thus, our observation that most patients 
have anti-ADAMTS13 IgG of multiple subclasses provides further 
evidence for the polyclonality of the antibody response.
In this study, we provide evidence of an association between 
the subclass distribution and inhibitory potential of anti-
ADAMTS13 antibodies. IgG4 levels showed a strong correlation 
with the inhibitory potential of the sample (Figure 5), the cor-
relation was already present at the time of the first acute episode. 
In addition, direct, head-to-head comparison of samples with 
or without IgG4-dominant anti-ADAMTS13 antibody response 
showed remarkable differences: equal amounts of IgG4-dominant 
ADAMTS13 antibodies had increased inhibitory potential, when 
compared to non-IgG4-dominant autoantibodies (Figure  7). 
This difference was unrelated to disease course, since the specific 
inhibitory potentials of IgG4-dominant samples from different 
disease stages showed no difference. Whether the increase of 
the inhibitory potential of IgG4 autoantibodies is a consequence 
of the altered subclass proportions (associated with different 
Fcγ receptor binding, half-life, or heavy-chain exchange), or a 
consequence of other parallel mechanisms, like affinity matura-
tion (resulting in increased affinity, avidity, and specificity), 
cannot be unequivocally determined from these data.
We found that total anti-ADAMTS13 IgG levels were lower 
during a relapse than during the first acute episode, this differ-
ence was statistically significant in the subset of patients who 
did not carry protective haplotypes (Figure  7C). Regarding 
the increase of the inhibitory potential of anti-ADAMTS13 
antibodies parallel to the switch to IgG4-dominance prior to 
a relapse, this finding suggests that, because of the stronger 
inhibitory capacity of autoantibodies, lower IgG concentra-
tions may be sufficient to cause severe ADAMTS13 deficiency 
resulting in increased risk of a TTP episode. The lower 
anti-ADAMTS13 IgG levels during a relapse, together with 
the lower proportion of complement-activating and Fcγ 
receptor-binding IgG subclasses, may contribute to the less 
severe clinical picture seen in relapse compared to the first 
acute episode (41).
Interestingly, total anti-ADAMTS13 IgG levels were higher in 
patients carrying protective HLA-DR-DQ haplotypes (DR7-DQ2, 
DR13-DQ6). There was no difference between patients carrying 
and not carrying risk haplotypes (DR11-DQ3, DR15-DQ6), 
though. Whereas there are accumulating data about the role 
of the DRB1*11 risk allele in the pathogenesis of TTP through 
efficient presentation of certain ADAMTS13-derived peptides by 
the DR11 molecule (22, 23, 42, 43), the mechanism by which the 
protective haplotypes lower the risk of developing TTP is to date 
obscure. There was no difference in the proportion of the IgG 
subclasses between groups of patients carrying or not carrying 
risk or protective haplotypes. Whether the samples of patients 
carrying protective haplotypes have weaker inhibitory capacities 
is an intriguing question; however, the low number of patients 
carrying protective haplotypes precluded statistical analysis in 
this study.
There are a number of strengths and potential limitations of 
this study. We determined the amount, subclass-distribution, 
and inhibitory potential of anti-ADAMTS13 IgG antibodies in 
anti-ADAMTS13 IgG-positive samples of a large and homo-
genous group of ADAMTS13-deficient acquired TTP patients. 
We compared the above parameters between disease stages and 
between patients carrying or not carrying risk or protective 
HLA-DR-DQ haplotypes. We found that whereas IgG1 was 
the dominant subclass in almost half of the patients during 
the first acute episode, IgG4 became the dominant subclass in 
all patients by the time of the first relapse. Interestingly, not 
a single relapse episode was linked to IgG1-dominant anti-
ADAMTS13 autoantibodies. The inhibitory potential of the 
samples correlated with the anti-ADAMTS13 IgG4 levels, and 
we provided direct evidence that IgG4 autoantibodies have 
stronger inhibitory potentials than non-IgG4 ones. No differ-
ences were observed in the subclass distribution of patients 
with different HLA-DR-DQ backgrounds, but the total anti-
ADAMTS13 IgG levels were markedly higher in patients car-
rying protective haplotypes than in those not carrying them. 
Potential limitations that may apply to this study include the 
descriptive, retrospective nature of the design, and the lack 
13
Sinkovits et al. Anti-ADAMTS13 IgG Subclasses in TTP
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1646
of prior sample size calculation. In addition, important sub-
groups, for example relapsing patients with available samples 
from acute disease, are limited in number. Taken all of these 
aspects together, our results provide further observational and 
experimental evidence for the presence of evolving immune 
response to ADAMTS13 in TTP.
These observations may, therefore, have important conse-
quences on the clinical management of acquired TTP. First, 
early and strong immunosuppressive therapy, with the goal to 
eradicate the ADAMTS13 inhibitor-producing B cell clones, 
seems to be indicated to avoid later affinity maturation and 
isotype switching. In addition, the analysis of anti-ADAMTS13 
subclasses may provide helpful information on risk of develop-
ment of ADAMTS13 deficiency, hence on follow-up protocol. 
Finally, it seems to be rational to study immunomodulating or 
cytokine-targeting therapies in the future to prevent the devel-
opment of matured, high affinity inhibitors to ADAMTS13 
in TTP.
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